Evidence map›Paper›PMID 38264645›Full record

ArticleFrontiers in immunology2023

Patient years lost due to cytomegalovirus serostatus mismatching in the scientific registry of transplant recipients.

Maheen Z Abidi, Jesse D Schold, Bruce Kaplan, Adriana Weinberg, Kristine M Erlandson, John S Malamon

Abstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Aging and Infections in Solid Organ Transplantation: Unchartered Territory.Transplant infectious disease : an official journal of the Transplantation Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maheen Z AbidiDepartment of Medicine, Division of Infectious Diseases, University of Colorado, Aurora, CO, United States.
Jesse D ScholdDepartment of Surgery, Division of Transplant Surgery, University of Colorado, Aurora, CO, United States.
Bruce KaplanDepartment of Surgery, Division of Transplant Surgery, University of Colorado, Aurora, CO, United States.
Adriana WeinbergDepartment of Medicine, Division of Infectious Diseases, University of Colorado, Aurora, CO, United States.
Kristine M ErlandsonDepartment of Medicine, Division of Infectious Diseases, University of Colorado, Aurora, CO, United States.
John S MalamonDepartment of Surgery, Division of Transplant Surgery, University of Colorado, Aurora, CO, United States.

Funding

CMV and CMV-Immune Responses in Geriatric Conditions Post-Kidney Transplant (CMV-GeriKT)K23AG073534 · NIA · UNIVERSITY OF COLORADO DENVER · PI ABIDI, MAHEEN ZEHRA · 2021 to 2025
$944k
Mentoring Across Disciplines: Aging and Infectious Diseases with a Focus on MobilityK24AG082527 · NIA · UNIVERSITY OF COLORADO DENVER · PI Kristine Mace Erlandson · 2023 to 2026
$768k
NIA NIH HHS K23 AG073534NIA NIH HHS K24 AG082527
6 · The paper itself

Abstract

Background: The cytomegalovirus (CMV) mismatch rate in deceased donor kidney transplant (DDKT) recipients in the US remains above 40%. Since CMV mismatching is common in DDKT recipients, the cumulative effects may be significant in the context of overall patient and graft survival. Our primary objective was to describe the short- and long-term risks associated with high-risk CMV donor positive/recipient negative (D+/R-) mismatching among DDKT recipients with the explicit goal of deriving a mathematical mismatching penalty. Methods: We conducted a retrospective, secondary analysis of the Scientific Registry of Transplant Recipients (SRTR) database using donor-matched DDKT recipient pairs (N=105,608) transplanted between 2011-2022. All-cause mortality and graft failure hazard ratios were calculated from one year to ten years post-DDKT. All-cause graft failure included death events. Survival curves were calculated using the Kaplan-Meier estimation at 10 years post-DDKT and extrapolated to 20 years to provide the average graft days lost (aGDL) and average patient days lost (aPDL) due to CMV D+/R- serostatus mismatching. We also performed an age-based stratification analysis to compare the relative risk of CMV D+ mismatching by age. Results: Among 31,518 CMV D+/R- recipients, at 1 year post-DDKT, the relative risk of death increased by 29% (p<0.001), and graft failure increased by 17% (p<0.001) as compared to matched CMV D+/R+ group (N=31,518). Age stratification demonstrated a significant increase in the risk associated with CMV mismatching in patients 40 years of age and greater. The aGDL per patient due to mismatching was 125 days and the aPDL per patient was 100 days. Conclusion: The risks of CMV D+/R- mismatching are seen both at 1 year post-DDKT period and accumulated throughout the lifespan of the patient, with the average CMV D+/R- recipient losing more than three months of post-DDKT survival time. CMV D+/R- mismatching poses a more significant risk and a greater health burden than previously reported, thus obviating the need for better preventive strategies including CMV serodirected organ allocation to prolong lifespans and graft survival in high-risk patients.

Indexed as

Cytomegalovirus InfectionsTransplant RecipientsAdultCytomegalovirusHumansRegistriesRetrospective StudiesCMVgraftkidneyserostatussurvivaltransplant

Identifiers

PMID38264645
PMCPMC10803440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.